Selecting one or more of the options below will update the content below.

Show / Hide Filters
Age Group
Type of Study
Study Format
Location
Target Population
  • Observational Study
    Online

    Patient-led Advisory Event Guiding Parkinson’s Research

    What is this Study about?

    Despite the clinical benefit and favourable safety profile of using focused ultrasound to manage tremor caused by Parkinson’s Disease, there is currently limited gender and cultural diversity among the patients we treat. We will use questionnaires and patient-led discussions to identify factors that prevent (i) women and (ii) a broader range of races and ethnicities from considering focused ultrasound to manage tremor.

    Eligibility Criteria

    Have been diagnosed with Parkinson's Disease; Must speak English

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Non-invasive brain stimulation to improve working memory in dementia: a proof-of-concept study

    What is this Study about?

    This study is exploring the viability of a potential treatment for cognitive decline in dementia by attempting to improve the brain's ability to hold onto information temporarily while doing things like reading lists, having a conversation, or problem-solving. The results from this study will inform future research in improving working memory and cognition in people living with dementia.

    Eligibility Criteria

    You are eligible to participate if you are:

    1) Diagnosed with Dementia and/or memory loss by a clinician

    2) Exhibit adequate oral communication skills and cognitive function sufficient to obtain a score over 10 on the Mini-Mental State Exam

    3) Over the age of 55

    4) Speaks English

    Recruitment End Date

    Find Out More
  • Observational Study
    Online

    Examining Social Support among Black Dementia Caregivers in the Greater Toronto Area

    What is this Study about?

    This study examines how Black family caregivers in the Greater Toronto Area experience and access social support while caring for a relative living with dementia. Using Straussian Grounded Theory informed by Critical Theory and Intersectionality, the research explores how factors such as race, culture, gender, and community shape caregiving experiences and support-seeking behaviours. Findings will be used to develop theory grounded in the lived experiences of Black caregivers, and to inform more culturally responsive dementia care policies, services, and supports across Canada. This study has been approved by the York University Research Ethics Board (Protocol 130, April 2026).

    Eligibility Criteria

    You are eligible to participate if you:

    • self-identify as Black (for example, African, Caribbean, Black Canadian, Afro-Latin, or another Black identity)
    • are 18 years of age or older
    • live in the Greater Toronto Area
    • provide unpaid care to a family member living with dementia
    • can speak and understand English well enough to take part in an interview

    Recruitment End Date

    Find Out More
  • Observational Study
    In-Person

    Levetiracetam for Persons at Risk for Alzheimer's Disease (ALEVIATE-2)

    What is this Study about?

    The goal of this study is to investigate whether very small doses of a drug called levetiracetam (LEV) may reduce abnormal brain signaling in the brain in individuals who are at an increased risk for developing Alzheimer's Disease. Only participants who show the abnormal brain signaling on a functional MRI (fMRI) scan of the brain will be enrolled in the study. Enrolled participants will receive 4 weeks of treatment with LEV and 4 weeks of treatment with placebo (a sugar pill). The study involves cognitive testing, genetic testing, bloodwork, ECGs, questionnaires and several brain imaging scans.

    Eligibility Criteria

    • Are between 55-85 years of age

    • Have a parent or sibling with Alzheimer’s disease or with dementia that may be due to Alzheimer’s disease (even if not diagnosed as such)

    • Feel your memory is getting worse

    • Get normal scores on tests of thinking and memory (will be done as part of the study)

    • Are able to undergo brain MRI scans

    • Have a study partner (friend or family member) willing to answer questionnaires about you

    • Show increased brain signaling during the screening fMRI scan (Note: We anticipate that most people who sign up for the study will NOT show the increased brain activity levels required to qualify for the study treatment)

    Recruitment End Date

    Find Out More
  • Observational Study
    Online

    Nature-based Virtual Reality Intervention for Depression in Alzheimer’s Disease (VRN-AD)

    What is this Study about?

    This study looks at how an at-home nature-based virtual reality (VR) program may help people living with Alzheimer’s Disease manage behavioural and psychological symptoms of dementia (BPSD), such as depression. Caregivers and/or study partners will have the option of taking part in the study and providing feedback regarding the VR intervention. This project will explore how virtual reality can be used as a non-pharmacological approach to prolong aging in place for individuals with BPSD, as BPSD contributes to rates of institutionalization.

    Eligibility Criteria

    • Are 50 years or older
    • Have been diagnosed with mild to early-moderate Alzheimer's disease (including mixed dementia)
    • Are medically stable and able to take part safely
    • Experience mild to moderate depressive symptoms
    • Feel comfortable using basic technology, such as a tablet or headset
    • Have access to Wi-Fi and a smart device (such as a phone or tablet) for online sessions and study apps
    • Have someone available to be present during all study sessions

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated with Alzheimer's Disease Psychosis

    What is this Study about?

    ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP).

    The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

    Eligibility Criteria

    Male or female participants aged 55 to 90 years of age
    Must have a study partner
    Presence of psychotic symptoms for at least 2 months before Screening.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)

    What is this Study about?

    The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).

    Eligibility Criteria

    Male or female participants aged 50 years of age to 90.
    Must have a study partner
    Participant- and/or Informant-reported history of cognitive decline with gradual onset and progression over the last 1 year before screening

    Recruitment End Date

    Find Out More
  • Clinical Trial
    In-Person

    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

    What is this Study about?

    The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

    Eligibility Criteria

    Male or female participants aged 55 years of age to 90.
    Must have a study partner
    History of agitation due to AD.

    Recruitment End Date

    Find Out More
  • Clinical Trial
    UHN - TO Western - Dr. Tartaglia

    A Phase 1, Randomized, Placebo-controlled Study With a Double Blind Period With Open-label Extension Period to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ALN-5288 in Adult Patients With Alzheimer

    What is this Study about?

    The purpose of this study is to:Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) and Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration

    Eligibility Criteria

    Male or female participants aged 40 to 80 years of age
    Has mild cognitive impairment (MCI) or dementia due to AD

    Recruitment End Date

    Find Out More